Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY2784544 · 3 trials · 8 indications
| Arm | Type | Description |
|---|---|---|
| 120 mg LY2784544 | EXPERIMENTAL | 120 milligram (mg) administered orally once daily for 6 cycles (168 days) |
| Part A: LY2784544 Dosing Regimen A | EXPERIMENTAL | LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days. |
| Part A: LY2784544 Dosing Regimen B | EXPERIMENTAL | LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses until reaching the highest dose a participant can tolerate. Each cycle is 28 days. |
| Part B: LY2784544 Dosing Regimen A | EXPERIMENTAL | LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days. |
| Part B: LY2784544 Dosing Regimen B | EXPERIMENTAL | LY2784544 will be taken by mouth per a specified schedule. Different participants will be treated at different doses from Part A that are determined to be safe and have potential clinical merit. Each cycle is 28 days. |
| LY2784544 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| 120 mg LY2784544 | DRUG | Administered orally |
| LY2784544 | DRUG | LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days. |
Inclusion Criteria: * Have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF) as defined by the World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms (Swerdlow et al. 2008) and meet the following additional subtype specific cr...
LY2784544 is an investigational small molecule being studied for the treatment of myeloproliferative disorders, including essential thrombocythemia, polycythemia vera, and primary myelofibrosis. It is also being evaluated in hematologic neoplasms. The drug is in clinical development and has not been approved by the FDA.
LY2784544 is a small molecule being developed for oncology. Its specific molecular target has not been disclosed in the available information. The drug is being studied in myeloproliferative disorders and hematologic neoplasms, but the exact mechanism of action is not specified.
LY2784544 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The drug is currently in Phase 1 and Phase 2 clinical trials for myeloproliferative disorders and related hematologic conditions.
LY2784544 is in Phase 1 and Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The clinical trials are studying the drug in patients with myeloproliferative disorders, including essential thrombocythemia, polycythemia vera, and myelofibrosis.
LY2784544 has been studied in three clinical trials. NCT01134120 is a Phase 1 study in myeloproliferative disorders. NCT01520220 is a Phase 1 study testing alternative dosing in myeloproliferative neoplasms. NCT01594723 is a Phase 2 study in hematologic neoplasms. All trials are completed or active but not recruiting.
Yes, LY2784544 is also known as 120 mg LY2784544. This alternative name refers to the specific dosage strength used in clinical studies. The drug is being investigated for the treatment of myeloproliferative disorders and hematologic neoplasms.